The Topology of Mutated Driver Pathways by Dridi, Raouf et al.
The Topology of Mutated Driver Pathways
Raouf Dridi∗1, Hedayat Alghassi†1, Maen Obeidat‡2, and
Sridhar Tayur§1
1Quantum Computing Group, Tepper School of Business,
Carnegie Mellon University, Pittsburgh, PA
2The University of British Columbia Center for Heart Lung
Innovation, St Paul’s Hospital Vancouver, Vancouver, BC
December 3, 2019
Abstract
Much progress has been made, and continues to be made, towards
identifying candidate mutated driver pathways in cancer. However, no
systematic approach to understanding how candidate pathways relate
to each other for a given cancer (such as Acute myeloid leukemia),
and how one type of cancer may be similar or different from another
with regard to their respective pathways (Acute myeloid leukemia vs.
Glioblastoma multiforme for instance), has emerged thus far. Our
work attempts to contribute to the understanding of space of pathways
through a novel topological framework. We illustrate our approach,
using mutation data (obtained from TCGA) of two types of tumors:
Acute myeloid leukemia (AML) and Glioblastoma multiforme (GBM).
We find that the space of pathways for AML is homotopy equivalent
to a sphere, while that of GBM is equivalent to a genus-2 surface. We
hope to trigger new types of questions (i.e., allow for novel kinds of
hypotheses) towards a more comprehensive grasp of cancer.
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1 Introduction
Let us begin by recalling a quote of Henri Poincare:
Science is built up of facts, as a house is built of stones; but an
accumulation of facts is no more a science than a heap of stones
is a house.
Cancer is driven by somatic mutations that target signaling and regulatory
pathways that control cellular proliferation and cell death [25]. Understand-
ing how this happens is of paramount importance in order to improve our
ability to intervene and attack cancer. Since the advent of DNA sequencing
technologies, our understanding has progressed enormously and resulted in
useful therapies.1
Notwithstanding the above, cancer morbidity is still very high and our under-
standing is still incomplete. Certainly, finding more relevant pathways will
be helpful. Indeed we have developed novel formulations and algorithms that
are computationally effective in doing so, a subject of our companion paper
([1] that builds on our work [2, 3]). We also believe that to start building a
house it is not enough to simply accumulate more stones faster. To that end,
1Current advances include the introduction of a single anti-cancer agents, which simply
bind with growth factor receptors stopping abnormal cell proliferations. For instance, in
the context of breast cancer, Herceptin antibody stops cells abnormal proliferation signals
by binding with the excess of growth factor receptors on the cell surface caused by point
mutations in the gene Her2. Gleevec is a second example. It is used to treat chronic
myeloid leukemia, which is a type of blood cell tumor due to an inappropriate gene fusion
product of a translocation in chromosomes 9 and 22. The resulting fusion gene BCR-ABL
has an increased kinase activity, resulting in an increase in proliferation signals. Similar to
Herceptin, Gleevec blocks the growth signals that the abnormal fusion gene generates and
thus prevents the cell proliferation. More sophisticated approaches include immunotherapy
that activates the immune system against cancer cells as well as the use of combinations
of therapeutic agents to attack multiple pathways fundamental in cancer development,
preventing resistance from occurring.
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in this paper, we look at whether the stones that we have identified so far
form patterns that can help us build a house, using methods from algebraic
topology (see Table 1).
The view we are taking here is also articulated in The Hallmarks of Can-
cer ([7]):
Two decades from now, having fully charted the wiring diagrams
of every cellular signaling pathway, it will be possible to lay out
the complete “integrated circuit of the cell” upon its current out-
line (Figure 1). We will then be able to apply the tools of math-
ematical modeling to explain how specific genetic lesions serve
to reprogram this integrated circuit... One day, we imagine that
cancer biology and treatment–at present, a patchwork quilt of cell
biology, genetics, histopathology, biochemistry, immunology, and
pharmacology–will become a science with a conceptual structure
and logical coherence that rivals that of chemistry or physics.
Pathways Algebraic topology
Regulatory/signaling pathway simplex
The Emergent integrated circuit of the cell simplicial complex Kε
Number of patients shared between two genes persistent parameter ε
Table 1: Correspondence between pathways and algebraic topology.
Our topological journey departs from the (well trodden) path that recognized
that signaling or regulatory pathways can be viewed as independent sets
(modulo some notion of tolerance) in a matrix with rows as patients and
columns as genes, which is used in determining new pathways via different
computational methods (see our companion paper [1] and previous works [21,
22, 5, 18, 10]). Our key insight is that these pathways (however discovered),
when grouped together, define a simplicial complex which is, pictorially, a
polytope with faces given by those pathways. This vantage point connects
us to the marvellous world of topology where simplicial complexes are the
prototypes of spaces with shapes. Our journey explores this notion of shape
in cancer genomics.
Our framework is built on this sequence of assignments:
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Figure 1: Cell circuitry, wiring pathways, resembles electronic integrated cir-
cuits. A full understanding of this picture will, one day, replace the present
day patchwork with a more rational approach based on conceptual struc-
tures and logical coherence similar to those encountered in chemistry and
physics [7].
MutationData → graphs → SpaceOfPathways → ShapeMeasurements
X 7→ G 7→ N (K) 7→ H∗(N (K))
where:
• G is the mutation graph. That is, is the graph defined by the set
of genes in X where two genes are connected if they have harboured
mutations for the same patients. K is the simplicial complex given
by the set of all independent sets of G. The underlying mathematics
detailed in [6] is based on the so-called Mayer-Vietoris construction,
which itself is articulated around clique covering the graph G. We
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prove in [6] that, for a large class of graphs, such coverings provide
most of the simplices of K.
• N (K) is the space of pathways. The facets (maximal independent sets)
of K are the pathways, and their nerve defines the space of pathways
N (K). Pictorially, the space of pathways is visualized through its 1-
skeleton of the graph with pathways as vertices and where two pathways
are connected by an edge if they intersect.
• H∗(N (K)) is the homology of the space of pathways, that is, the shape
measurements of the space of pathways.
We have applied our approach to two different mutation data obtained from
TCGA: Acute myeloid leukemia (AML) [14] and Glioblastoma multiforme
(GBM) [13]. For both the data, we have computed the assignment
tumor→ space of pathways (1.1)
using persistent homology.2 Our calculation shows that the space of path-
ways for AML mutation data is homotopy equivalent to a sphere, while in the
case of GBM data, the space of pathways is homotopy equivalent to figure
eight (genus-2 surface).
2 Related works
The motivation for the present work originates from the work of the Raphael
Lab, centred around the Dendrix algorithm [23], and its later improvements
including CoMEt [9]. Both algorithms are in widespread use in whole-genome
analysis–for instance, in [16, 17, 4, 20]. Building on those foundations, our
work extends in the following two directions: First, the two key notions of
exclusivity and coverage are abstracted here by the two simplicial complexes
Kε and Kη or, more precisely, by the filtrations of simplicial complexes Kε0 ⊂
· · · ⊂ Kε` and Kη0 ⊂ · · · ⊂ Kη`′ , where we allow the two parameters to vary:
ε0 ≤ ε ≤ ε` and η0 ≤ η ≤ η`′ . We do so because, in reality, the assumptions
2In the language of Homotopy Type Theory (HoTT) [19], this procedure translates into:
tumor 7→ (∞, 1)−category. This (∞, 1)−category is an (∞, 1)−topos (a logical structure)
in the sense of Lurie [12], so it obeys the axioms of HoTT.
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that driver pathways exhibit both high coverage and high exclusivity need
not to be strictly satisfied. The functoriality of persistent homology, which
takes the two filterations as input, handles this elegantly; we decide on the
values of these two parameters after computing the barcodes. This type
of analysis is not present in the aforementioned works. Second, motivated
by the naturality of the constructions, the present paper goes beyond the
computational aspects and ventures into the conceptuality of cancer. We
have introduced the notion of the topological space of pathways N , together
with its homology spaces, as a paradigm to rationalize the extraordinary
complexity of cancer. To the best of our knowledge, this is a “provocative”
idea that has not been explored before.
Another related set of works is [11] and [15] (from Stanford’s applied topology
group), which also use algebraic topology tools in cancer. However, they
differ from ours on two counts: the nature of the problem treated and the
methodology used. The algorithm introduced, called Mapper, is a topological
clustering algorithm, and it is not based on persistent homology. Mapper was
used to identify a subgroup of breast cancers with excellent survival, solely
based on topological properties of the data.3
3 Connecting to algebraic topology
Different errors occurring during data preparation (i.e., sequencing step, etc.)
affect the robustness of the results. This implies that the computed pathways
are likely to be affected by these errors and can not be considered as a robust
finding without explicitly modeling the error in our constructions. To that
end, the assignment we mentioned above is done as follows:
1. We think about the number of patients that are shared between two
genes as a parameter ε (thus, absolute exclusivity corresponds to taking
this parameter to zero).
2. Instead of applying our procedure once, we apply it for a range of
values of the exclusivity parameter ε. That is, we consider a filtration
of graphs (instead of one):
3Commercial applications of this approach in various different areas of practice are
tackled through Ayasdi.
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Gε0 ⊂ · · · ⊂ Gε` (3.1)
where for each graph Gε two genes are connected if they have harboured
mutations concurrently for at least ε patients. This yields a second
filtration of simplicial complexes (we call such a filtration, a persistent
pathway complex)
Kε0 ⊂ · · · ⊂ Kε` (3.2)
where Kε is one of the three complexes we define below.
3. Measure the shape (the homology) of the different pathway spaces and
then “average” the shape measurements that are obtained.
This (practical) version of homology is what we refer to as persistent homol-
ogy. It tracks the persistent topological features through a range of values
of the parameter; genuine topological properties persist through the change
of the parameter whilst noisy observations do not (all of these will be made
precise below). The key point is that the mapping Gε 7→ Kε is functorial;
that is, it sends a whole filtration (i.e., 3.1) into another filtration (i.e., 3.2).
In other words, it is not only sending graphs to simplicial complexes but it is
also preserving their relations. This functoriality is at the heart of persistent
homology.
3.1 The Gene-Patient graph
Consider a mutation data for m tumors (i.e., patients), where each of the
n genes is tested for a somatic mutation in each patient. To this data we
associate a mutation matrix B with m rows and n columns, where each row
represents a patient and each column represents a gene. The entry Big in
row i and column g is equal to 1 if patient i harbours a mutation in gene g
and it is 0 otherwise. For a gene g, we define the fiber
Patients(g) = the set of patients in which g has mutated. (3.3)
Definition 1 The mutation graph associated to B and ε > 0 is the graph
Gε whose vertex set is the set of genes and whose edges are pairs of genes
(g, g′) such that
|Patients(g) ∩ Patients(g′)| ≥ ε. (3.4)
7
There are evidences that pathways can be treated as independent sets of
mutation graphs (although not stated graph-theoretically) [24, 26].
3.2 The space of pathways
We would like to assign to the mutation graph an independence complex.
We present below two different functorial ways to do so.
Definition 2 Given a mutation graph Gε, its persistent pathway complex Kε
is the independence complex of Gε (or equivalently, the clique complex of Gε,
the complement of Gε).
We also define the persistent pathway complex Kη.
Definition 3 The persistent pathway complex Kη is defined as follows. Fix
ε = ε0 and let G = Gε0. The complex Kη is the complex generated by all
independent sets S of G with coverage∑
g∈S
Patients(g) ≥ η (3.5)
where the counting g ∈ S is done without redundancy.
The following definition is also valid for the persistent pathway complex Kη.
Definition 4 The space of pathways of a persistent pathway complex Kε
is the nerve generated by the facets of the complex, that is, the simplicial
complex where {i0, · · · , i`} is a simplex if and only if the facets indexed with
i0, · · · , i` have a non empty intersection. We denote the space of pathways
by Nε.
The space of pathways is visualized through its 1-skeleton: the graph with
pathways as vertices, and two pathways are connected if they intersect (see
Figures 3 and 4).
3.3 A primer on persistent homology
Recall that our plan is to compute the persistent homology of the indepen-
dence complex Kε. We have explained that this is simply computing the
homology of Kε for a range of increasing values of the parameter ε. In this
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section, we explain this notion of homology (which we have introduced as
measurements of the shape of the space Kε). For simplicity, we drop out the
subscript ε from the complex Kε. It is also more convenient to introduce
homology for clique complexes (for independence complexes, it suffices to
replace, everywhere below, cliques with independent sets).
The homology of the simplicial complex K (now a clique complex of G) is a
sequence of Z-vector spaces (i.e., vector spaces with integer coefficients):
H∗(K) := H0(K), H1(K), H2(K), . . . (3.6)
defined as follows:
• The zeroth vector space H0(K) is spanned by all connected components
of K; thus, the dimension β0 := dim(H0(K)) gives the number of
connected components of the space.
• The first homology space H1(K) is spanned by all closed chains of edges
(cycles) in G which are not triangles – see Figure 2; in this case, the
dimension β1 := dim(H1(K)) gives the number of “holes” in the space.
• Similarly, the second space H2(K) is spanned by all 2-dimensional en-
closed three dimensional “voids” that are not tetrahedra (as in Figure 3
below).
Higher dimensional spaces are defined in a similar way (although less visual).
Their dimensions count non trivial high dimensional voids. The dimensions
βi := dim(Hi(K)) are called Betti numbers and provide the formal descrip-
tion of the concept of shape measurements.4
We move now to the notion of persistent homology and make it a bit more
precise. For that, let us reintroduce the persistent parameter ε and let Kε be
again an independence complex. It is clear that if |Patients(g)∩Patients(g′)| ≥
ε1 and ε1 ≥ ε2 then the pair (g, g′), which is an edge in Gε1 , is also is an edge
in Gε2 . This means that Gε1 is a subgraph of Gε2 ; thus, we have Kε2 ⊂ Kε1
4In textbooks, one typically starts with a continuous space (for instance, a doughnut
shaped surface) and then triangulizes it, yielding the simplicial complex K. The homology
of the continuous space is the homology of its discretization K that we introduced picto-
rially above. Appendix A, on page 20, explains how to compute homology using quantum
computers or QUBO-solvers such as [2].
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Figure 2: The graph has two connected components, which implies β0 = 2.
It also has two cycles that are not triangles; thus, β1 = 2. Higher Betti
numbers are zero.
Figure 3: The graph has two connected components, giving β0 = 2. It also
has 7 cycles that are not triangles, which yields β1 = 7. Higher Betti numbers
are zero here as well. Now, if the different sides of the hexagonal prism
(right component) are covered with triangles, then we get instead β1 = 0
and β2 = 1.
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whenever ε1 ≥ ε2 (since an independent set for a given graph is also an
independent set for any of its subgraphs). The mapping ε 7→ Kε is functorial.
It turns out that homology itself is functorial and all this functoriality is the
mathematical reason that the following is correct: one can track the Betti
numbers over a range of values ε1 ≥ ε2 ≥ ε3 ≥ · · · and consider the subrange
where the Betti numbers are not changing (significantly). Pathways within
this subrange are considered to have passed our test and declared robust
computations.
4 Real mutation data
We have applied our approach to two mutation data (formulations and algo-
rithms are available in [1]): Acute myeloid leukemia [14] and Glioblastoma
multiforme [13]. For both data, we have computed the assignment tumor 7→
pathways through persistent pathway complexes (thus, declared robust out-
put). The complete result is presented in long tables given in the Appendix.
Interestingly, our calculation also shows that AML data is homotopy equiv-
alent to a sphere while GBM data is homotopy equivalent to figure eight
(genus-2 surface).
4.1 Acute myeloid leukemia data
The data has a cohort of 200 patients and 33 genes ([14]). We have chosen
the coverage threshold η = 80 patient. We also neglected all genes that have
fewer than 6 patients. These numbers are chosen based on the stability of
barecodes for pairs (ε, η) ≥ (6, 80), while barecodes for pairs less than (6, 80)
exhibit strong variations. This is also consistent with the fact that choosing
genes with fewer than 5 or 6 patients is not common in such studies (genes
with low numbers of patients are not considered robust enough, and are very
prone to errors. This extra precaution is commonly used in the field). Now
for the numbers of patients and coverage we have chosen, the Betti numbers
are computed for various values of ε in the table below:
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ε |Nε| density(Nε) βi
1 6 0.86 1, 0, 0, · · ·
2 84 0.97 1, 0, 0, · · ·
3 50 1 1, 0, 0, · · ·
Figure 4 below gives the 1-skeleton of the nerve Nε := N (Kε) for ε = 1.
The Betti numbers βi are not changing; thus, ε = 1 is a reasonable choice.
Recall that each node represents a pathway and two pathways are connected
if they intersect (as sets of genes). We have used different colors to represent
different pathways as described in the table below (no other meaning for the
coloring).
Figure 4: The 1-skeleton of the nerve Nε for ε = 1 for AML data. In this case, the
nerve is homotopy equivalent to the sphere. The different pathways represented
by the nodes are given in the table above.
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Color Genes in the pathway
Blue ’PML.RARA’, ’MYH11.CBFB’, ’RUNX1.RUNX1T1’, ’TP53’, ’NPM1’, ’RUNX1’
Blue light ’PML.RARA’, ’MYH11.CBFB’, ’RUNX1.RUNX1T1’, ’TP53’, ’NPM1’, ’MLL.PTD’
Orange ’PML.RARA’, ’MYH11.CBFB’, ’RUNX1.RUNX1T1’, ’DNMT3A’
Orange light ’Other Tyr kinases’, ’MYH11.CBFB’, ’MLL.PTD’, ’NPM1’
Green ’MLL-X fusions’, ’TP53’, ’FLT3’
Green light ’Other Tyr kinases’, ’MYH11.CBFB’, ’DNMT3A’, ’MLL-X fusions’
4.2 Glioblastoma multiforme data
The second mutation data is taken from [13]. It has 84 patients and around
100 genes. Approximately, 70% of the genes have very low coverage so we
removed them from the data; precisely, we have removed all genes with fewer
than 10 patients. We have used the complex Kη, with ε fixed to 7 because
lower values don’t exhibit stable topologies; that is, barcodes are essentially
one point long. This is a different choice of complex from the complex Kε
that we used with the previous AML data, which interestingly doesn’t yield
noticeable stability–a possible explanation of this is the small size of the data
(i.e., number of patients). Recall that the definitions of the two complexes
are given on page 8 (definitions 2 and 3). In the table below, one can see that
the topology stabilizes for the first three values of η. Any choice of pathways
within this range is considered robust (proportionate to the small size of the
data).
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η |Nη| density(Nη) βi
66 15 0.73 1, 2, 0, · · ·
67 14 0.74 1, 2, 0, · · ·
68 12 0.72 1, 2, 0, · · ·
69 6 0.6 1, 0, 0, · · ·
70 50 1 1, 0, 0, · · ·
Figure 5: The nerve for the space of pathways for GBM data (see table below for
the legend). The barcodes are stable in the first part of the table, which indicates
that the nerve is homotopy equivalent to a genus-2 surface.
The following table provides the legend for the Figure 5 corresponding to
the GBM data:
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Color Genes in the pathway
blue RB1, NF1, CYP27B1, CDKN2B
blue light RB1, NF1, MDM2, AVIL-CTDSP2, CDKN2B
orange TP53, MDM2, OS9, CDKN2A
orange light TP53, MDM2, AVIL-CTDSP2, CDKN2A
green TP53, MDM2, DTX3, CDKN2A
green light RB1, NF1, CDK4, CDKN2B
brown TP53, CDK4, CDKN2A
brown light TP53, CYP27B1, CDKN2A
purple TP53, MDM2, AVIL-CTDSP2, MTAP
purple light TP53, MDM2, DTX3, MTAP
red RB1, NF1, MDM2, OS9, CDKN2B
pink TP53, MDM2, OS9, MTAP
5 Conclusion
The main goal of this paper was to suggest a study of the space of cancer
pathways, using the natural language of algebraic topology. We hope that
the consideration of the pathways collectively, that is, as a topological space,
helps to reveal novel relations between these pathways. Indeed, we have
seen that the homology in the case of AML indicates that the mutation data
has the shape of a sphere.5 However, in the case of GBM, the final set of
pathways has the topology of a double torus (or, more technically, a genus-2
surface). This intriguing observation raises the question of whether these
facts translate into a new biological understanding about cancer. Studying
the space of pathways of other cancers will be illuminating as well, if they
5Using a different visual representation, Vogelstein found AML to be very different from
other cancers. Indeed, that has allowed many scientists to speculate that such genetically
simple tumors are more susceptible to drugs, and thus intrinsically more curable.
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also show similar structures, and we can classify cancers by the topology
of their mutated driver pathways. This is an example of the new type of
hypotheses one can now formulate about the data. Eventually, our goal
(recalling Poincare) is to help build a house by revealing patterns among the
stones. Let us close with a quote from The Emperor of All Maladies (page
458):
The third,6 and arguably most complex, new direction for cancer
medicine is to integrate our understanding of aberrant genes and
pathways to explain the behavior of cancer as a whole, thereby
renewing the cycle of knowledge, discovery and therapeutic inter-
vention.
References
[1] H. Alghassi, R. Dridi, A. G. Robertson, and S. Tayur. Quantum and
Quantum-inspired Methods for de novo Discovery of Altered Cancer
Pathways. bioRxiv:10.1101/845719, Nov. 2019.
[2] H. Alghassi, R. Dridi, and S. Tayur. GAMA: A Novel Algorithm for
Non-Convex Integer Programs. arXiv:1907.10930, July 2019.
[3] H. Alghassi, R. Dridi, and S. Tayur. Graver Bases via Quan-
tum Annealing with Application to Non-Linear Integer Programs.
arXiv:1902.04215, Feb. 2019.
[4] F. Bertucci, C. K. Y. Ng, A. Patsouris, N. Droin, S. Piscuoglio, N. Car-
buccia, J. C. Soria, A. T. Dien, Y. Adnani, M. Kamal, S. Garnier,
G. Meurice, M. Jimenez, S. Dogan, B. Verret, M. Chaffanet, T. Bach-
elot, M. Campone, C. Lefeuvre, H. Bonnefoi, F. Dalenc, A. Jacquet,
M. R. De Filippo, N. Babbar, D. Birnbaum, T. Filleron, C. Le Tourneau,
and F. Andre´. Genomic characterization of metastatic breast cancers.
Nature, 569(7757):560–564, 2019.
[5] G. Ciriello, E. Cerami, C. Sander, and N. Schultz. Mutual exclusivity
analysis identifies oncogenic network modules. Genome Res, 22(2):398–
406, 2012.
6The first is targeted therapy on the mutated pathways, as we mentioned in the Intro-
duction. The second is cancer prevention through identifying preventable carcinogens.
16
[6] R. Dridi and H. Alghassi. Homology computation of large point clouds
using quantum annealing. Arxiv:1512.09328. 2015.
[7] D. Hanahan and R. A. Weinberg. The hallmarks of cancer. Cell,
100(1):57–70, 2016.
[8] M. W. Johnson, M. H. S. Amin, S. Gildert, T. Lanting, F. Hamze,
N. Dickson, R. Harris, A. J. Berkley, J. Johansson, P. Bunyk, E. M.
Chapple, C. Enderud, J. P. Hilton, K. Karimi, E. Ladizinsky, N. Ladizin-
sky, T. Oh, I. Perminov, C. Rich, M. C. Thom, E. Tolkacheva, C. J. S.
Truncik, S. Uchaikin, J. Wang, B. Wilson, and G. Rose. Quantum an-
nealing with manufactured spins. Nature, 473(7346):194–198, 05 2011.
[9] M. D. Leiserson, H.-T. Wu, F. Vandin, and B. J. Raphael. CoMEt:
a statistical approach to identify combinations of mutually exclusive
alterations in cancer. Genome Biology, 16(1):160, 2015.
[10] M. D. M. Leiserson, H.-T. Wu, F. Vandin, and B. J. Raphael. Comet: A
statistical approach to identify combinations of mutually exclusive alter-
ations in cancer. In T. M. Przytycka, editor, Research in Computational
Molecular Biology, 2015.
[11] P. Y. Lum, G. Singh, A. Lehman, T. Ishkanov, M. Vejdemo-Johansson,
M. Alagappan, J. Carlsson, and G. Carlsson. Extracting insights from
the shape of complex data using topology. Scientific Reports, 3:1236 EP
–, 02 2013.
[12] J. Lurie. Higher Topos Theory (AM-170). Princeton University Press,
2009.
[13] T. C. G. A. R. Network. Comprehensive genomic characteriza-
tion defines human glioblastoma genes and core pathways. Nature,
455(7216):1061–1068, 2008.
[14] T. C. G. A. R. Network. Genomic and epigenomic landscapes of adult
de novo acute myeloid leukemia. New England Journal of Medicine,
368(22):2059–2074, 2013.
[15] M. Nicolau, A. J. Levine, and G. Carlsson. Topology based data analysis
identifies a subgroup of breast cancers with a unique mutational profile
17
and excellent survival. Proceedings of the National Academy of Sciences
of the United States of America, 108 17:7265–70, 2011.
[16] P. A. Northcott, I. Buchhalter, A. S. Morrissy, V. Hovestadt, J. Weis-
chenfeldt, T. Ehrenberger, S. Gro¨bner, M. Segura-Wang, T. Zichner,
V. A. Rudneva, H.-J. Warnatz, N. Sidiropoulos, A. H. Phillips, S. Schu-
macher, K. Kleinheinz, S. M. Waszak, S. Erkek, D. T. W. Jones, B. C.
Worst, M. Kool, M. Zapatka, N. Ja¨ger, L. Chavez, B. Hutter, M. Bieg,
N. Paramasivam, M. Heinold, Z. Gu, N. Ishaque, C. Ja¨ger-Schmidt,
C. D. Imbusch, A. Jugold, D. Hu¨bschmann, T. Risch, V. Amstislavskiy,
F. G. R. Gonzalez, U. D. Weber, S. Wolf, G. W. Robinson, X. Zhou,
G. Wu, D. Finkelstein, Y. Liu, F. M. G. Cavalli, B. Luu, V. Ramaswamy,
X. Wu, J. Koster, M. Ryzhova, Y.-J. Cho, S. L. Pomeroy, C. Herold-
Mende, M. Schuhmann, M. Ebinger, L. M. Liau, J. Mora, R. E. McLen-
don, N. Jabado, T. Kumabe, E. Chuah, Y. Ma, R. A. Moore, A. J.
Mungall, K. L. Mungall, N. Thiessen, K. Tse, T. Wong, S. J. M. Jones,
O. Witt, T. Milde, A. Von Deimling, D. Capper, A. Korshunov, M.-L.
Yaspo, R. Kriwacki, A. Gajjar, J. Zhang, R. Beroukhim, E. Fraenkel,
J. O. Korbel, B. Brors, M. Schlesner, R. Eils, M. A. Marra, S. M. Pfister,
M. D. Taylor, and P. Lichter. The whole-genome landscape of medul-
loblastoma subtypes. Nature, 547:311 EP –, 07 2017.
[17] N. Riaz, P. Blecua, R. S. Lim, R. Shen, D. S. Higginson, N. Weinhold,
L. Norton, B. Weigelt, S. N. Powell, and J. S. Reis-Filho. Pan-cancer
analysis of bi-allelic alterations in homologous recombination dna repair
genes. Nature Communications, 8(1):857, 2017.
[18] E. Szczurek and N. Beerenwinkel. Modeling mutual exclusivity of cancer
mutations. In R. Sharan, editor, Research in Computational Molecular
Biology, 2014.
[19] The Univalent Foundations Program. Homotopy Type Theory: Univa-
lent Foundations of Mathematics. https://homotopytypetheory.org/
book, Institute for Advanced Study, 2013.
[20] J. van de Haar, S. Canisius, M. K. Yu, E. E. Voest, L. F. Wessels, and
T. Ideker. Identifying epistasis in cancer genomes: A delicate affair.
Cell, 177(6):1375 – 1383, 2019.
18
[21] F. Vandin, P. Clay, E. Upfal, and B. J. Raphael. Discovery of mutated
subnetworks associated with clinical data in cancer. In Biocomputing
2012: Proceedings of the Pacific Symposium, Kohala Coast, Hawaii,
USA, January 3-7, 2012, pages 55–66, 2012.
[22] F. Vandin, E. Upfal, and B. Raphael. De novo discovery of mutated
driver pathways in cancer. Genome Research, 22(2):375–385, 2012.
[23] F. Vandin, E. Upfal, and B. J. Raphael. De novo discovery of mutated
driver pathways in cancer. Genome Research, 22(2):375–385, 2012.
[24] B. Vogelstein and K. W. Kinzler. Cancer genes and the pathways they
control. Nat Med, 10(8):789–799, 2004.
[25] R. Weinberg. The Biology of Cancer. W. W. Norton & Company, 2013.
[26] C.-H. Yeang, F. McCormick, and A. Levine. Combinatorial patterns
of somatic gene mutations in cancer. The FASEB Journal, 22(8):2605–
2622, 2008.
[27] A. Zomorodian and G. Carlsson. Localized homology. Computational
Geometry, 41(3):126 – 148, 2008.
19
A Appendix
This appendix has three parts. In the first part, we review an efficient pro-
cedure for computing homology groups. The remaining two parts give the
obtained list of pathways for GBM and AML data, respectively.
A.1 Computing homology on quantum computers
We provide the following material (from [6]) for easy access. We review how
the homology spaces H∗(X) are computed. In principle, the formal defini-
tions of homology that can be found in any algebraic topology textbook,
are sufficient for computations. However, we point here to a more efficient
approach based on Mayer-Vietoris blow-up complexes. We formulate finding
optimal Mayer-Vietoris blow-up complexes as Quadratic Unconstrained Bi-
nary Optimizations (QUBO). QUBO-solvers (such as the D-Wave quantum
annealer [8] or quantum-inspired classical solvers such as [2]) are now avail-
able for calculations.
Let C = {Ki}i∈I be a cover of K by simplicial subcomplexes Ki ⊆ K;
here again we have dropped the subscript ε from Kε for simplicity. For J ⊆ I,
we define KJ = ∩j∈JKj.
Definition 5 The Mayer-Vietoris blow-up complex of the simplicial complex
K and cover C, is defined by:
KC =
⋃
J⊆I
⋃
σ∈KJ
σ × J.
A basis for the k−chains Ck(KC) is {σ ⊗ J ∈ KC| dimσ + card J = n}. The
boundary of a cell σ ⊗ J is given by: ∂(σ ⊗ J) = ∂σ ⊗ J + (−1)dimσσ ⊗ ∂J.
Simply put, the simplicial complex KC is the set of the “original” simplices
in addition to the ones we get by blowing up common simplices. These are
of the form σ ⊗ J in the definition above. In Figure 6, the yellow vertex d
common to the two subcomplexes {K1, K2} is blown-up into an edge d⊗ 12,
and the edge bc is blown-up into the “triangle” bc ⊗ 01. In Figure 7, the
vertex a common to three subcomplexes {K0, K1, K2} is blown-up into the
triangle a⊗ 012.
We will not prove it here, but the projection KC → K is a homotopy
equivalence and induces an isomorphism H∗(KC) ' H∗(K) [27]. The key
20
Figure 6: (Top) The simplicial complex K is the depicted graph. (Middle)
K is covered with K0, K1, and K2. (Bottom) The blow-up complex of the
cover depicted in the middle picture. After the blow-up, the edges b⊗01, c⊗
01, d⊗ 12, and the triangle bc⊗ 01 appear.
Figure 7: The triangle a × 012 appears after blowing-up the cover of the
middle picture.
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point is that the boundary map of the simplicial complex KC (which re-
places K by the homotopy equivalence) has a nice block form suitable for
parallel rank computation. As an example, let us consider again the simpli-
cial complex K depicted in Figure 6. First, C0(K
C), the space of vertices of
the blow-up complex KC, is spanned by the vertices
{a⊗ 0, b⊗ 0, c⊗ 0, b⊗ 1, c⊗ 1, d⊗ 1, d⊗ 2, e⊗ 2},
that is, all vertices of K taking into account the partition they belong to.
The space of edges C1(K
C) is spanned by
{ab⊗ 0, bc⊗ 0, bc⊗ 1, cd⊗ 1, de⊗ 2, b⊗ 01, c⊗ 01, d⊗ 12},
which is the set of the “original” edges (edges of the form σ ⊗ j with j ∈
J = {0, 1, 2} and σ is an edge in K) and the new ones resulting from blow-
ups, that is, those of the form v ⊗ ij where v is a vertex in Kj ∩Kj (if the
intersection is empty, the value of boundary map is just 0). The matrix of
the boundary map ∂0 with respect to the given ordering is then:
∂0 =

−1 0 0 0 0 0 0 0
1 −1 0 0 0 −1 0 0
0 1 0 0 0 0 −1 0
0 0 −1 0 0 1 0 0
0 0 1 −1 0 0 1 0
0 0 0 1 0 0 0 −1
0 0 0 0 −1 0 0 1
0 0 0 0 1 0 0 0

Clearly, one can now row-reduce each coloured block independently. There
might be remainders, that is, zero rows except for the intersection part. We
collect all such rows in one extra matrix and row-reduce it at the end and
aggregate. For the second boundary matrix we need to determine C2(K
C).
The 2-simplices are of three forms. First, the original ones (those of the form
σ ⊗ j with σ ∈ C2(K); in this example there is none) then those of the form
σ×{i, j}, with σ being in Ki∩Kj. And finally, those of the form v⊗{i, j, k},
with v ∈ Ki∩Kj ∩Kk (there is none in this example, but Figure 5 has one).
We get C2(K
C) = 〈bc⊗ 01〉; thus, there is no need for parallel computation.
Finally, for efficient computations, it is necessary that the homologies of the
smaller blocks are easy to compute. This is where the QUBO-solver comes
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in. It is used to obtain a “good” cover C by computing a clique cover of
the original graph G (plus a completion step). It is easy to see that such
coverings do, indeed, come with trivial block homologies [6].
A.2 GBM pathways list
The table below reports the final pathways in Figure 5. Details on the data,
the parameters, and how the pathways are computed using persistent homol-
ogy, can be found in Subsection 4.2 on page 13.
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Pathway coverage η
RB1 , NF1 , CYP27B1 , CDKN2B 70
RB1 , NF1 , MDM2 , AVIL-CTDSP2 , CDKN2B 69
TP53 , MDM2 , OS9 , CDKN2A 69
TP53 , MDM2 , AVIL-CTDSP2 , CDKN2A 69
TP53 , MDM2 , DTX3 , CDKN2A 69
RB1 , NF1 , CDK4 , CDKN2B 69
RB1 , NF1 , MDM2 , OS9 , CDKN2B 68
TP53 , MDM2 , OS9 , MTAP 68
TP53 , MDM2 , AVIL-CTDSP2 , MTAP 68
TP53 , MDM2 , DTX3 , MTAP 68
TP53 , CDK4 , CDKN2A 68
TP53 , CYP27B1 , CDKN2A 68
TP53 , CDK4 , MTAP 67
TP53 , CYP27B1 , MTAP 67
RB1 , NF1 , CYP27B1 , CDKN2A 66
RB1 , NF1 , MDM2 , OS9 , CDKN2A 65
RB1 , NF1 , MDM2 , AVIL-CTDSP2 , CDKN2A 65
RB1 , NF1 , MDM2 , DTX3 , CDKN2B 65
RB1 , NF1 , CDK4 , CDKN2A 65
RB1 , NF1 , CYP27B1 , MTAP 65
RB1 , NF1 , MDM2 , OS9 , MTAP 64
RB1 , NF1 , MDM2 , AVIL-CTDSP2 , MTAP 64
RB1 , NF1 , CDK4 , MTAP 64
RB1 , NF1 , MDM2 , DTX3 , CDKN2A 62
RB1 , NF1 , MDM2 , DTX3 , MTAP 61
TP53 , MDM2 , AVIL-CTDSP2 , SEC61G 60
RB1 , NF1 , EGFR , OS9 60
TP53 , MDM2 , OS9 , SEC61G 59
TP53 , MDM2 , DTX3 , SEC61G 59
PTEN , IFNA21 , MDM2 , AVIL-CTDSP2 58
TP53 , MDM2 , AVIL-CTDSP2 , IFNA21 58
RB1 , NF1 , EGFR , DTX3 58
PTEN , IFNA21 , CYP27B1 58
PTEN , IFNA21 , MDM2 , OS9 57
TP53 , MDM2 , OS9 , IFNA21 57
TP53 , MDM2 , DTX3 , IFNA21 57
PTEN , IFNA21 , CDK4 57
RB1 , NF1 , MDM2 , AVIL-CTDSP2 , SEC61G 55
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PTEN , IFNA21 , MDM2 , DTX3 55
TP53 , MDM2 , AVIL-CTDSP2 , ELAVL2 55
RB1 , NF1 , MDM2 , OS9 , SEC61G 54
TP53 , MDM2 , OS9 , ELAVL2 54
TP53 , MDM2 , DTX3 , ELAVL2 54
RB1 , NF1 , MDM2 , AVIL-CTDSP2 , IFNA21 53
TP53 , CDK4 , IFNA21 53
TP53 , CDK4 , ELAVL2 53
TP53 , CYP27B1 , IFNA21 53
TP53 , CYP27B1 , ELAVL2 53
RB1 , NF1 , MDM2 , OS9 , IFNA21 52
RB1 , NF1 , MDM2 , DTX3 , SEC61G 52
RB1 , NF1 , MDM2 , AVIL-CTDSP2 , ELAVL2 51
RB1 , NF1 , CYP27B1 , IFNA21 51
RB1 , NF1 , CYP27B1 , ELAVL2 51
RB1 , NF1 , MDM2 , OS9 , ELAVL2 50
RB1 , NF1 , CDK4 , IFNA21 50
RB1 , NF1 , CDK4 , ELAVL2 50
RB1 , NF1 , MDM2 , DTX3 , IFNA21 49
RB1 , NF1 , MDM2 , DTX3 , ELAVL2 47
A.3 AML pathways list
The following table gives the list of all 65 pathways of N1 (Figure 4) and
their coverage. Details about the data and how the pathways are obtained
using persistent homology can be found in Section 3.1. All pathways listed
below passed our robustness test.
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Pathway Coverage
PML.RARA , MYH11.CBFB , RUNX1.RUNX1T1 , TP53 , NPM1 , RUNX1 123
PML.RARA , MYH11.CBFB , RUNX1.RUNX1T1 , TP53 , NPM1 , MLL.PTD 113
PML.RARA , MYH11.CBFB , RUNX1.RUNX1T1 , DNMT3A 85
Other Tyr kinases , MYH11.CBFB , MLL.PTD , NPM1 83
MLL-X fusions , TP53 , FLT3 81
Other Tyr kinases , MYH11.CBFB , DNMT3A , MLL-X fusions 80
PML.RARA , MYH11.CBFB , Cohesin , Other modifiers 78
MLL-X fusions , DNMT3A , RUNX1.RUNX1T1 , MYH11.CBFB 78
PML.RARA , MYH11.CBFB , RUNX1.RUNX1T1 , TP53 , PHF6 , IDH1 75
Other myeloid TFs , MYH11.CBFB , Cohesin , Other modifiers 74
Other Tyr kinases , FLT3 , MLL-X fusions 74
PML.RARA , MYH11.CBFB , RUNX1.RUNX1T1 , TP53 , IDH2 70
PML.RARA , MYH11.CBFB , RUNX1.RUNX1T1 , CEBPA , RUNX1 66
PML.RARA , MYH11.CBFB , RUNX1.RUNX1T1 , TP53 , PHF6 , MLL.PTD 65
Other myeloid TFs , MYH11.CBFB , TP53 , RUNX1.RUNX1T1 , RUNX1 65
PML.RARA , PTPs , IDH2 , TET2 65
PML.RARA , MYH11.CBFB , TET2 , IDH2 64
MLL-X fusions , TP53 , RUNX1.RUNX1T1 , MYH11.CBFB , IDH2 63
PML.RARA , MYH11.CBFB , RUNX1.RUNX1T1 , CEBPA , PHF6 , MLL.PTD 62
PML.RARA , KRAS/NRAS , PHF6 , MLL.PTD , KIT 62
MLL-X fusions , TP53 , RUNX1.RUNX1T1 , MYH11.CBFB , IDH1 62
MLL-X fusions , TP53 , RUNX1.RUNX1T1 , MYH11.CBFB , RUNX1 62
Other myeloid TFs , MYH11.CBFB , TP53 , RUNX1.RUNX1T1 , PHF6 , MLL.PTD 61
PML.RARA , KRAS/NRAS , PHF6 , MLL.PTD , RUNX1.RUNX1T1 61
PML.RARA , KIT , TP53 , IDH2 60
PML.RARA , KIT , TP53 , RUNX1 59
MLL-X fusions , TET2 , MYH11.CBFB , IDH2 57
PML.RARA , PTPs , IDH2 , KIT 56
PML.RARA , KIT , CEBPA , RUNX1 56
PML.RARA , KIT , TP53 , PHF6 , MLL.PTD 55
PML.RARA , PTPs , IDH2 , RUNX1.RUNX1T1 55
PML.RARA , PTPs , RUNX1 , KIT 55
Other myeloid TFs , KIT , TP53 , RUNX1 55
PML.RARA , PTPs , RUNX1 , RUNX1.RUNX1T1 54
MLL-X fusions , TP53 , KIT , IDH2 53
PML.RARA , KIT , CEBPA , PHF6 , MLL.PTD 52
MLL-X fusions , TP53 , RUNX1.RUNX1T1 , MYH11.CBFB , MLL.PTD 52
Ser-Tyr kinases , RUNX1.RUNX1T1 , PTPs , MLL.PTD 52
MLL-X fusions , TP53 , KIT , RUNX1 52
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Pathway Coverage
Other myeloid TFs , KIT , TP53 , PHF6 , MLL.PTD 51
PML.RARA , WT1 , RUNX1.RUNX1T1 , TP53 51
PML.RARA , MYH11.CBFB , TET2 , PHF6 50
PML.RARA , KIT , Cohesin 50
Other Tyr kinases , MYH11.CBFB , IDH2 , MLL-X fusions 49
Other Tyr kinases , MYH11.CBFB , IDH1 , MLL-X fusions 48
Other Tyr kinases , MYH11.CBFB , MLL.PTD , PHF6 , Other myeloid TFs 47
Other Tyr kinases , KRAS/NRAS , PHF6 , MLL.PTD 47
Other myeloid TFs , MYH11.CBFB , TET2 , PHF6 46
MLL-X fusions , Cohesin , MYH11.CBFB 46
Other myeloid TFs , KIT , Cohesin 46
Other Tyr kinases , MYH11.CBFB , IDH1 , PHF6 45
PML.RARA , PTPs , MLL.PTD , KIT 45
PML.RARA , WT1 , TET2 45
PML.RARA , PTPs , MLL.PTD , RUNX1.RUNX1T1 44
MLL-X fusions , TP53 , RUNX1.RUNX1T1 , WT1 44
MLL-X fusions , Cohesin , KIT 43
MLL-X fusions , TP53 , KIT , MLL.PTD 42
Other Tyr kinases , PTPs , IDH2 41
Other Tyr kinases , MYH11.CBFB , MLL.PTD , MLL-X fusions 38
MLL-X fusions , TET2 , WT1 38
Spliceosome , CEBPA 37
Spliceosome , PTPs 36
Spliceosome , Other myeloid TFs 36
Other Tyr kinases , WT1 , MLL-X fusions 30
Other Tyr kinases , PTPs , MLL.PTD 30
The following long table gives the assignment tumor 7→ list of pathways for
the AML data. For each tumor we assign a robust (in our topological sense)
set of pathways. More specifically, for a tumor (sample ID) i, the second
column gives the list of all pathways that have passed our robustness test.
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Sample ID Pathways Cyto
0 0, 1, 2, 6, 8, 11, 12, 13, 15, 16, 18, 19, 23, 24, 25, 27, 28, 29, 30, 31, 33, 35, 40, 41, 42, 51, 52, 53 Good
1 0, 1, 2, 7, 8, 11, 12, 13, 14, 17, 18, 20, 21, 22, 23, 30, 33, 36, 37, 40, 53, 54 Good
2 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 26, 36, 41, 43, 44, 45, 46, 47, 48, 50, 58 Good
3 0, 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 13, 14, 16, 17, 18, 20, 21, 22, 26, 36, 41, 43, 44, 45, 47, 48, 50, 58 Good
4 0, 1, 2, 3, 5, 6, 8, 10, 11, 12, 13, 15, 16, 18, 19, 23, 24, 25, 27, 28, 29, 30, 31, 33, 35, 40, 41, 42, 43, 44, 45, 46, 50, 51, 52, 53, 57, 58, 63, 64 Good
5 0, 1, 2, 4, 6, 8, 10, 11, 12, 13, 15, 16, 18, 19, 23, 24, 25, 27, 28, 29, 30, 31, 33, 35, 40, 41, 42, 51, 52, 53 Good
6 0, 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 20, 21, 22, 26, 27, 30, 31, 33, 36, 37, 41, 43, 44, 45, 47, 48, 50, 51, 53, 57, 58, 61, 64 Good
7 0, 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 18, 19, 20, 21, 22, 23, 24, 25, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 42, 43, 44, 45,
46, 49, 50, 51, 53, 54, 55, 56, 57, 58, 60, 61, 62, 63, 64 Good
8 0, 1, 2, 4, 7, 8, 10, 11, 12, 13, 14, 17, 18, 20, 21, 22, 23, 30, 33, 36, 37, 40, 53, 54 Good
9 0, 1, 2, 6, 8, 11, 12, 13, 15, 16, 18, 19, 23, 24, 25, 27, 28, 29, 30, 31, 33, 35, 40, 41, 42, 51, 52, 53 Good
10 0, 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 13, 14, 16, 17, 18, 20, 21, 22, 26, 36, 41, 43, 44, 45, 47, 48, 50, 58 Good
11 0, 1, 2, 6, 8, 11, 12, 13, 15, 16, 18, 19, 23, 24, 25, 27, 28, 29, 30, 31, 33, 35, 40, 41, 42, 51, 52, 53, 60, 61, 62 Good
12 40, 52, 54, 59, 60, 61, 62, 63 Good
13 0, 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 24, 25, 26, 27, 28, 29, 31, 32, 34, 35, 36, 38, 39, 41, 42, 43, 44, 45, 47, 48, 49,
50, 51, 55, 56, 58 Good
14 0, 1, 2, 4, 6, 8, 10, 11, 12, 13, 15, 16, 18, 19, 23, 24, 25, 27, 28, 29, 30, 31, 33, 35, 40, 41, 42, 51, 52, 53 Good
15 0, 1, 2, 6, 8, 11, 12, 13, 15, 16, 18, 19, 23, 24, 25, 27, 28, 29, 30, 31, 33, 35, 40, 41, 42, 51, 52, 53 Good
16 0, 1, 2, 3, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 17, 18, 20, 21, 22, 23, 30, 33, 36, 37, 40, 42, 43, 44, 45, 46, 48, 49, 50, 53, 54, 55, 57, 58, 63, 64 Good
17 0, 1, 2, 4, 6, 8, 10, 11, 12, 13, 15, 16, 18, 19, 23, 24, 25, 27, 28, 29, 30, 31, 33, 35, 40, 41, 42, 51, 52, 53 Good
18 0, 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 24, 25, 26, 27, 28, 29, 31, 32, 34, 35, 36, 37, 38, 39, 41, 42, 43, 44, 45, 47, 48,
49, 50, 51, 55, 56,
58, 60, 61, 62 Good
19 0, 1, 2, 6, 8, 11, 12, 13, 15, 16, 18, 19, 23, 24, 25, 27, 28, 29, 30, 31, 33, 35, 40, 41, 42, 51, 52, 53 Good
20 0, 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 13, 14, 16, 17, 18, 20, 21, 22, 26, 36, 41, 43, 44, 45, 47, 48, 50, 58 Good
21 0, 1, 2, 7, 8, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 47, 49,
51, 52, 53, 54, 55, 56, 59, 60, 61, 62 Good
22 32, 4, 39, 9, 10, 45, 14, 47, 49, 22, 62 Good
23 0, 1, 2, 6, 8, 11, 12, 13, 15, 16, 18, 19, 23, 24, 25, 27, 28, 29, 30, 31, 33, 35, 40, 41, 42, 51, 52, 53 Good
24 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 18, 20, 21, 22, 26, 36, 41, 43, 44, 45, 47, 48, 50, 58 Good
25 0, 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 24, 25, 26, 27, 28, 29, 31, 32, 34, 35, 36, 38, 39, 40, 41, 42, 43, 44, 45, 47, 48,
49, 50, 51, 52, 54, 55, 56, 58, 59, 63 Good
26 0, 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 13, 14, 16, 17, 18, 19, 20, 21, 22, 23, 26, 36, 41, 43, 44, 45, 46, 47, 48, 50, 58 Good
27 0, 1, 2, 6, 8, 9, 11, 12, 13, 14, 15, 16, 18, 19, 22, 23, 24, 25, 27, 28, 29, 30, 31, 32, 33, 35, 39, 40, 41, 42, 45, 47, 49, 51, 52, 53, 62 Good
28 0, 1, 2, 4, 6, 8, 10, 11, 12, 13, 15, 16, 18, 19, 23, 24, 25, 27, 28, 29, 30, 31, 33, 35, 40, 41, 42, 51, 52, 53 Good
29 0, 1, 2, 6, 7, 8, 9, 11, 12, 13, 14, 17, 18, 20, 21, 22, 23, 30, 33, 36, 37, 40, 42, 48, 49, 53, 54, 55 Good
30 0, 1, 2, 4, 5, 6, 7, 8, 10, 11, 12, 13, 15, 16, 17, 18, 19, 20, 21, 23, 24, 25, 26, 27, 28, 29, 30, 31, 33, 34, 35, 36, 38, 40, 41, 42, 43, 44, 48,
51, 52, 53, 54, 55, 56, 58, 59, 63 Good
31 37 Good
32 0, 1, 2, 3, 5, 6, 7, 8, 9, 11, 12, 13, 14, 16, 17, 18, 20, 21, 22, 26, 36, 41, 43, 44, 45, 47, 48, 50, 58 Good
33 0, 1, 2, 3, 5, 6, 8, 10, 11, 12, 13, 15, 16, 18, 19, 23, 24, 25, 27, 28, 29, 30, 31, 33, 35, 40, 41, 42, 43, 44, 45, 46, 50, 51, 52, 53, 57, 58, 63, 64 Good
34 0, 1, 2, 6, 7, 8, 9, 11, 12, 13, 14, 17, 18, 20, 21, 22, 23, 30, 33, 36, 37, 40, 42, 48, 49, 53, 54, 55 Good
35 0, 1, 2, 4, 6, 8, 10, 11, 12, 13, 15, 16, 18, 19, 23, 24, 25, 27, 28, 29, 30, 31, 33, 35, 40, 41, 42, 51, 52, 53 Good
36 10, 4 Good
37 0, 1, 2, 3, 5, 7, 8, 64, 44, 61, 15, 50, 51, 20, 53, 57, 33, 27, 37, 30, 31 Intermediate
38 35, 6, 39, 8, 41, 13, 46, 45, 50, 18, 19, 9, 22, 23, 47, 29 Intermediate
39 0, 32, 34, 43, 38, 33, 11, 12, 14, 15, 16, 17, 21, 25, 24, 57, 26, 27, 28, 30, 31 Intermediate
40 0, 11, 12, 14, 15, 16, 17, 21, 24, 25, 26, 27, 28, 30, 31, 32, 33, 34, 37, 38, 43, 57 Intermediate
41 35, 60, 12, 46, 18, 19, 23, 28 Intermediate
42 0, 1, 2, 3, 5, 7 Intermediate
43 0, 1, 2, 3, 4, 5, 6, 7, 9, 10, 48, 49, 55, 42 Intermediate
44 0, 6, 9, 12, 14, 15, 16, 19, 21, 23, 25, 26, 28, 31, 32, 33, 38, 41, 42, 46, 47, 48, 49, 52, 55, 59, 60, 61, 62 Intermediate
45 0, 1, 10, 3, 4 Intermediate
46 2, 43, 5, 7, 11, 34, 46, 15, 16, 17, 19, 23, 24, 57, 26, 27, 30, 37 Intermediate
47 10, 4 Intermediate
48 0, 1, 3, 4, 6, 9, 10, 15, 27, 30, 31, 33, 37, 42, 48, 49, 51, 53, 55, 57, 61, 64 Intermediate
49 0, 1, 2, 3, 4, 5, 7, 10 Intermediate
50 0, 1, 2, 3, 4, 5, 7, 41, 10, 15, 16, 59, 52, 26, 47 Intermediate
51 0, 1, 3, 4, 6, 9, 10, 15, 27, 30, 31, 33, 37, 42, 48, 49, 51, 53, 55, 57, 61, 64 Intermediate
52 0, 1, 3, 37, 6, 33, 64, 9, 42, 15, 48, 49, 51, 53, 55, 57, 27, 61, 30, 31 Intermediate
53 2, 59, 5, 7, 41, 15, 16, 52, 26, 47 Intermediate
54 0, 1, 2, 3, 4, 5, 7, 10, 46, 19, 23 Intermediate
55 0, 1, 2, 3, 4, 5, 6, 7, 9, 10, 48, 49, 55, 42 Intermediate
56 0, 1, 2, 3, 4, 5, 7, 10 Intermediate
57 1, 3, 8, 13, 18, 19, 20, 22, 23, 29, 35, 36, 37, 39, 44, 45, 46, 50, 51, 53, 56, 58, 64 Intermediate
58 0, 2, 5, 6, 7, 8, 9, 12, 13, 14, 18, 19, 21, 22, 23, 25, 28, 29, 31, 32, 33, 35, 37, 38, 39, 41, 42, 45, 46, 47, 48, 49, 50, 55, 60, 61, 62 Intermediate
59 2, 5, 7, 46, 19, 23, 60, 61, 62 Intermediate
60 0, 1, 3, 4, 6, 9, 10, 48, 49, 55, 42 Intermediate
61 0, 1, 3, 4, 6, 40, 9, 10, 48, 49, 52, 54, 55, 59, 42, 63 Intermediate
62 10, 4 Intermediate
63 28, 18, 35, 12, 60 Intermediate
64 0, 8, 11, 12, 14, 15, 16, 17, 20, 21, 24, 25, 26, 27, 28, 30, 31, 32, 33, 34, 38, 43, 44, 50, 57, 60, 61, 62 Intermediate
65 48, 2, 59, 5, 6, 7, 8, 41, 42, 55, 44, 15, 16, 49, 50, 52, 9, 20, 26, 47 Intermediate
66 32, 2, 5, 7, 9, 39, 45, 14, 47, 49, 22, 62 Intermediate
67 0, 1, 2, 3, 5, 6, 7, 9, 42, 48, 49, 55 Intermediate
68 0, 1, 2, 3, 4, 5, 7, 10 Intermediate
69 0, 1, 2, 3, 5, 6, 7, 40, 9, 44, 8, 50, 52, 54, 20, 59, 63 Intermediate
70 0, 1, 34, 3, 11, 46, 15, 16, 17, 19, 43, 23, 24, 57, 26, 27, 30 Intermediate
71 32, 39, 9, 45, 14, 47, 49, 22, 62 Intermediate
72 0, 1, 34, 3, 4, 10, 11, 15, 16, 17, 43, 24, 57, 26, 27, 30 Intermediate
73 0, 1, 3, 8, 44, 50, 20 Intermediate
74 0, 1, 3, 4, 41, 10, 15, 16, 59, 52, 26, 47 Intermediate
75 35, 4, 60, 10, 12, 18, 28 Intermediate
76 0, 1, 2, 3, 4, 5, 7, 10 Intermediate
77 1, 2, 3, 4, 5, 6, 7, 9, 10, 13, 15, 16, 18, 19, 22, 23, 26, 29, 35, 36, 37, 39, 41, 45, 46, 47, 51, 52, 53, 56, 58, 59, 64 Intermediate
78 10, 4 Intermediate
79 2, 5, 7 Intermediate
80 0, 1, 2, 3, 4, 5, 7, 9, 10, 39, 45, 14, 47, 49, 32, 22, 62 Intermediate
81 34, 4, 5, 38, 7, 10, 43, 44, 48, 17, 20, 21, 54, 55, 56, 36, 26, 59, 58, 63 Intermediate
82 4, 6, 8, 9, 10, 44, 50, 20 Intermediate
83 2, 5, 7, 9, 14, 15, 22, 27, 30, 31, 32, 33, 37, 39, 45, 47, 49, 51, 53, 57, 61, 62, 64 Intermediate
28
84 0, 1, 3, 4, 10, 12, 13, 14, 18, 19, 21, 22, 23, 25, 28, 29, 31, 32, 33, 35, 36, 37, 38, 39, 40, 45, 46, 51, 52, 53, 54, 56, 58, 59, 63, 64 Intermediate
85 9, 10, 4, 6 Intermediate
86 0, 1, 3 Intermediate
87 0, 1, 10, 3, 4 Intermediate
88 34, 43, 37, 11, 15, 16, 17, 62, 24, 57, 26, 27, 60, 61, 30 Intermediate
89 0, 1, 3 Intermediate
90 0, 1, 2, 3, 5, 7, 8, 64, 44, 61, 15, 50, 51, 20, 53, 57, 33, 27, 37, 30, 31 Intermediate
91 0, 1, 2, 3, 5, 6, 7, 9, 12, 15, 18, 19, 23, 27, 28, 30, 31, 33, 35, 37, 40, 42, 46, 48, 49, 51, 52, 53, 54, 55, 57, 59, 60, 61, 63, 64 Intermediate
92 0, 32, 34, 43, 38, 33, 11, 12, 14, 15, 16, 17, 21, 25, 24, 57, 26, 27, 28, 30, 31 Intermediate
93 59, 37, 41, 47, 16, 52, 26, 15, 60, 61, 62 Intermediate
94 0, 1, 2, 3, 4, 5, 7, 8, 9, 10, 39, 44, 45, 14, 47, 49, 50, 20, 32, 22, 62 Intermediate
95 0, 1, 2, 3, 5, 6, 7, 9, 42, 55, 46, 48, 49, 19, 23 Intermediate
96 0, 32, 38, 33, 12, 14, 21, 25, 28, 31 Intermediate
97 59, 41, 46, 47, 16, 19, 52, 23, 26, 15 Intermediate
98 0, 1, 10, 3, 4 Intermediate
99 0, 1, 3, 37, 8, 44, 50, 20 Intermediate
100 0, 1, 2, 4, 5, 7, 8, 11, 13, 14, 17, 20, 21, 22, 24, 25, 29, 32, 34, 36, 37, 38, 39, 40, 54, 56 Intermediate
101 28, 18, 35, 12, 60 Intermediate
102 0, 1, 3, 8, 44, 50, 20 Intermediate
103 0, 32, 38, 33, 12, 14, 21, 25, 28, 31 Intermediate
104 34, 4, 5, 38, 7, 10, 43, 44, 48, 17, 20, 21, 54, 55, 56, 36, 26, 59, 58, 63 Intermediate
105 32, 51, 34, 35, 38, 39, 60, 42, 61, 49, 19, 56, 55, 24, 25, 27, 28, 29, 62, 31 Intermediate
106 0, 1, 34, 3, 37, 11, 15, 16, 17, 43, 24, 57, 26, 27, 30 Intermediate
107 0, 3, 5, 10, 12, 14, 21, 25, 28, 31, 32, 33, 38, 43, 44, 45, 46, 50, 57, 58, 63, 64 Intermediate
108 4, 5, 6, 7, 9, 10, 12, 17, 18, 20, 21, 26, 28, 34, 35, 36, 38, 43, 44, 48, 54, 55, 56, 58, 59, 60, 63 Intermediate
109 3, 5, 10, 12, 15, 16, 18, 26, 28, 35, 41, 43, 44, 45, 46, 47, 50, 52, 57, 58, 59, 60, 63, 64 Intermediate
110 4, 40, 10, 52, 54, 59, 63 Intermediate
111 0, 1, 2, 3, 4, 5, 7, 10 Intermediate
112 0, 1, 3, 4, 5, 6, 7, 9, 10, 17, 19, 20, 21, 23, 26, 34, 36, 38, 43, 44, 46, 48, 54, 55, 56, 58, 59, 63 Intermediate
113 0, 1, 3 Intermediate
114 0, 1, 3, 12, 13, 14, 18, 19, 21, 22, 23, 25, 28, 29, 31, 32, 33, 35, 36, 37, 38, 39, 45, 46, 51, 53, 56, 58, 60, 61, 62, 64 Intermediate
115 0, 1, 2, 3, 5, 7, 46, 19, 23 Intermediate
116 1, 2, 3, 4, 5, 7, 10, 11, 13, 15, 16, 17, 18, 19, 22, 23, 24, 26, 27, 29, 30, 34, 35, 36, 37, 39, 43, 45, 46, 51, 53, 56, 57, 58, 64 Intermediate
117 2, 4, 37, 6, 7, 9, 10, 61, 48, 49, 55, 60, 42, 62, 5 Intermediate
118 0, 1, 2, 3, 5, 7 Intermediate
119 0, 1, 3, 40, 52, 54, 59, 60, 61, 62, 63 Intermediate
120 0, 32, 34, 43, 38, 33, 11, 12, 14, 15, 16, 17, 21, 25, 24, 57, 26, 27, 28, 30, 31 Intermediate
121 34, 4, 37, 38, 7, 63, 10, 43, 44, 48, 17, 20, 21, 54, 55, 56, 36, 26, 59, 58, 5 Intermediate
122 0, 1, 3, 4, 8, 10, 13, 18, 19, 22, 23, 29, 35, 39, 40, 41, 45, 46, 47, 50, 52, 54, 59, 63 Intermediate
123 0, 1, 2, 3, 4, 5, 6, 7, 9, 10, 48, 49, 55, 42 Intermediate
124 0, 1, 3, 8, 44, 46, 50, 19, 20, 23 Intermediate
125 48, 59, 4, 6, 41, 10, 55, 47, 16, 49, 52, 9, 26, 15, 42 Intermediate
126 0, 1, 2, 3, 4, 5, 7, 10 Intermediate
127 1, 2, 3, 5, 6, 7, 9, 13, 18, 19, 22, 23, 29, 35, 36, 37, 39, 42, 45, 46, 48, 49, 51, 53, 55, 56, 58, 64 Intermediate
128 0, 32, 38, 33, 12, 14, 21, 25, 28, 31 Intermediate
129 1, 3, 6, 9, 13, 15, 16, 18, 19, 22, 23, 26, 29, 35, 36, 37, 39, 41, 42, 45, 46, 47, 48, 49, 51, 52, 53, 55, 56, 58, 59, 64 Intermediate
130 28, 18, 35, 12, 60 Intermediate
131 2, 43, 5, 6, 7, 9, 11, 34, 15, 16, 17, 24, 57, 26, 27, 30 Intermediate
133 0, 1, 2, 3, 4, 5, 7, 10 Intermediate
134 0, 6, 8, 9, 12, 13, 14, 18, 19, 21, 22, 23, 25, 28, 29, 31, 32, 33, 35, 38, 39, 40, 41, 45, 46, 47, 50, 52, 54, 59, 63 Intermediate
135 32, 2, 35, 5, 7, 60, 39, 12, 45, 14, 47, 49, 18, 22, 9, 28, 62 Intermediate
136 3, 5, 6, 9, 10, 15, 16, 26, 37, 41, 43, 44, 45, 46, 47, 50, 52, 57, 58, 59, 63, 64 Intermediate
137 4, 5, 7, 9, 10, 14, 17, 19, 20, 21, 22, 23, 26, 32, 34, 36, 38, 39, 43, 44, 45, 46, 47, 48, 49, 54, 55, 56, 58, 59, 62, 63 Intermediate
138 1, 3, 11, 13, 15, 16, 17, 18, 19, 22, 23, 24, 26, 27, 29, 30, 34, 35, 36, 37, 39, 43, 45, 46, 51, 53, 56, 57, 58, 64 Intermediate
140 0, 1, 2, 3, 4, 5, 6, 7, 9, 10, 15, 27, 30, 31, 33, 37, 42, 48, 49, 51, 53, 55, 57, 61, 64 Intermediate
141 0, 1, 2, 3, 5, 6, 7, 9, 60, 61, 62 Intermediate
142 0, 32, 38, 33, 12, 14, 21, 25, 28, 31 Intermediate
143 0, 1, 2, 6, 8, 11, 12, 13, 15, 16, 18, 19, 23, 24, 25, 27, 28, 29, 30, 31, 33, 35, 37, 40, 41, 42, 51, 52, 53 Intermediate
144 0, 6, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 38, 39, 41, 43, 45, 46, 47, 50, 57 Intermediate
145 2, 43, 5, 7, 11, 34, 46, 15, 16, 17, 19, 23, 24, 57, 26, 27, 30 Intermediate
146 0, 1, 3, 4, 6, 60, 10, 55, 12, 48, 49, 18, 35, 9, 28, 42 Intermediate
147 0, 32, 59, 37, 38, 33, 31, 41, 12, 46, 47, 16, 19, 52, 14, 23, 25, 26, 15, 28, 21 Intermediate
148 0, 1, 3 Intermediate
149 37 Intermediate
150 1, 3, 11, 13, 15, 16, 17, 18, 19, 22, 23, 24, 26, 27, 29, 30, 34, 35, 36, 37, 39, 43, 45, 46, 51, 53, 56, 57, 58, 64 Intermediate
151 2, 5, 7, 8, 44, 50, 20 Intermediate
152 0, 1, 34, 3, 11, 15, 16, 17, 43, 24, 57, 26, 27, 30 N.D.
153 0, 1, 3, 4, 5, 8, 10, 11, 13, 14, 17, 20, 21, 22, 24, 25, 29, 32, 34, 36, 38, 39, 40, 43, 44, 45, 46, 50, 54, 56, 57, 58, 63, 64 N.D.
154 0, 1, 2, 3, 4, 5, 6, 7, 9, 10, 60, 61, 62 N.D.
155 0, 6, 9, 11, 12, 14, 15, 16, 17, 21, 24, 25, 26, 27, 28, 30, 31, 32, 33, 34, 38, 42, 43, 48, 49, 55, 57 N.D.
157 0, 1, 2, 4, 5, 6, 7, 8, 9, 11, 13, 14, 15, 16, 17, 20, 21, 22, 24, 25, 26, 29, 32, 34, 36, 37, 38, 39, 40, 41, 42, 47, 48, 49, 52,
54, 55, 56, 59 Poor
158 9, 10, 4, 6 Poor
159 0, 1, 4, 8, 11, 13, 14, 17, 20, 21, 22, 24, 25, 29, 32, 34, 36, 38, 39, 40, 54, 56, 60, 61, 62 Poor
160 0, 1, 4, 8, 11, 13, 14, 17, 20, 21, 22, 24, 25, 29, 32, 34, 36, 38, 39, 40, 54, 56 Poor
161 10, 4 Poor
162 0, 1, 3, 4, 37, 10 Poor
163 32, 39, 9, 45, 14, 47, 49, 22, 62 Poor
164 9, 11, 12, 14, 15, 16, 17, 18, 22, 24, 26, 27, 28, 30, 32, 34, 35, 37, 39, 40, 43, 45, 47, 49, 52, 54, 57, 59, 60, 62, 63 Poor
165 37 Poor
166 0, 1, 4, 6, 8, 9, 11, 13, 14, 17, 20, 21, 22, 24, 25, 29, 32, 34, 36, 38, 39, 40, 54, 56 Poor
167 19, 46, 23 Poor
168 59, 37, 6, 41, 47, 16, 52, 9, 26, 15 Poor
169 9, 6 Poor
170 0, 1, 4, 8, 11, 13, 14, 15, 17, 20, 21, 22, 24, 25, 27, 29, 30, 31, 32, 33, 34, 36, 37, 38, 39, 40, 51, 53, 54, 56, 57, 61, 64 Poor
171 60, 37, 62, 61 Poor
172 10, 4 Poor
174 46, 19, 23, 60, 61, 62 Poor
175 0, 1, 4, 8, 11, 13, 14, 17, 19, 20, 21, 22, 23, 24, 25, 29, 32, 34, 36, 38, 39, 40, 46, 54, 56 Poor
176 0, 1, 4, 6, 8, 9, 11, 13, 14, 15, 17, 20, 21, 22, 24, 25, 27, 29, 30, 31, 32, 33, 34, 36, 37, 38, 39, 40, 51, 53, 54, 56, 57, 61, 64 Poor
177 2, 5, 7, 8, 44, 46, 50, 19, 20, 23 Poor
178 4, 6, 40, 9, 10, 61, 48, 49, 52, 54, 55, 59, 60, 42, 62, 63 Poor
179 2, 5, 7, 9, 11, 14, 15, 16, 17, 22, 24, 26, 27, 30, 32, 34, 39, 43, 45, 47, 49, 57, 62 Poor
180 2, 59, 4, 5, 7, 8, 41, 10, 44, 15, 16, 50, 52, 20, 26, 47 Poor
29
181 60, 61, 62 Poor
183 4, 5, 7, 10, 17, 20, 21, 26, 34, 36, 37, 38, 43, 44, 48, 54, 55, 56, 58, 59, 60, 61, 62, 63 Poor
184 0, 1, 2, 3, 4, 5, 7, 8, 10, 19, 20, 24, 25, 27, 28, 29, 31, 32, 34, 35, 38, 39, 42, 44, 49, 50, 51, 55, 56 Poor
186 0, 1, 4, 6, 8, 9, 11, 13, 14, 17, 20, 21, 22, 24, 25, 29, 32, 34, 36, 38, 39, 40, 54, 56 Poor
187 0, 32, 2, 6, 5, 38, 7, 8, 12, 44, 14, 50, 20, 21, 9, 25, 33, 28, 31 Poor
188 32, 51, 34, 35, 6, 38, 39, 9, 42, 49, 19, 56, 55, 24, 25, 27, 28, 29, 31 Poor
189 0, 1, 4, 8, 11, 13, 14, 17, 20, 21, 22, 24, 25, 29, 32, 34, 36, 38, 39, 40, 54, 56 Poor
190 0, 1, 3, 4, 5, 8, 10, 11, 13, 14, 17, 20, 21, 22, 24, 25, 29, 32, 34, 36, 38, 39, 40, 43, 44, 45, 46, 50, 54, 56, 57, 58, 63, 64 Poor
191 0, 1, 4, 8, 11, 12, 13, 14, 17, 18, 19, 20, 21, 22, 23, 24, 25, 28, 29, 32, 34, 35, 36, 38, 39, 40, 46, 54, 56, 60 Poor
192 4, 5, 7, 8, 10, 13, 15, 17, 18, 19, 20, 21, 22, 23, 26, 27, 29, 30, 31, 33, 34, 35, 36, 37, 38, 39, 41, 43, 44, 45, 46, 47, 48,
50, 51, 53, 54,55, 56, 57, 58, 59, 61, 63, 64 Poor
194 0, 1, 4, 6, 8, 9, 11, 13, 14, 17, 20, 21, 22, 24, 25, 29, 32, 34, 36, 38, 39, 40, 54, 56 Poor
195 0, 1, 4, 8, 11, 13, 14, 17, 20, 21, 22, 24, 25, 29, 32, 34, 36, 38, 39, 40, 54, 56 Poor
196 0, 1, 2, 3, 5, 6, 7, 9, 46, 19, 23, 60, 61, 62 Poor
197 2, 35, 5, 6, 7, 8, 12, 44, 18, 60, 50, 20, 9, 28 Poor
198 0, 1, 4, 8, 11, 13, 14, 17, 20, 21, 22, 24, 25, 29, 32, 34, 36, 37, 38, 39, 40, 54, 56 Poor
199 8, 44, 50, 20 Poor
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